The Food and Drug Administration recently approved Accuray Inc.'s Radixact Treatment Delivery Platform.
The Radixact system includes the Accuray Precision Treatment Planning System and iDMS Data Management Systems. These new software solutions offer a faster, more efficient delivery of radiation to a wider range of cancer patients when paired with the Radixact hardware.
The Radixact system contains a linear accelerator, megavoltage computed tomography imaging and helical treatment delivery, which allows clinicians to apply extremely conformal doses of radiation to any size target. The precision of the system also spares normal healthy tissue during each treatment.
The Accuracy Precision Treatment Planning System enables clinicians to adapt radiation delivery based on changes in tumor size, shape and location within the patient.
"The Radixact System gives the radiation therapy team expanded capabilities across the widest range of patient cases, from the routine to the most complex, with precision, speed and efficient workflows," said Joshua H. Levine, president and CEO Accuray.
The company, based in Sunnyvale, Calif., expects to release the Radixact System for commercial use within the next three months.
More articles on supply chain:
AstraZeneca takes $80M hit after CDC rules nasal spray vaccines ineffective
St. Jude Medical introduces new pacemaker technology
Allergy drug launch postponed after failed dosage study